Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI

Elena Pak,Kyu Sung Choi,Seung Hong Choi,Chul-Kee Park,Tae Min Kim,Sung-Hye Park,Joo Ho Lee,Soon-Tae Lee,Inpyeong Hwang,Roh-Eul Yoo,Koung Mi Kang,Tae Jin Yun,Ji-Hoon Kim,Chul-Ho Sohn
DOI: https://doi.org/10.3348/kjr.2020.1433
IF: 7.109
2021-01-01
Korean Journal of Radiology
Abstract:OBJECTIVE: To develop a radiomics risk score based on dynamic contrast-enhanced (DCE) MRI for prognosis prediction in patients with glioblastoma.MATERIALS AND METHODS: One hundred and fifty patients (92 male [61.3%]; mean age ± standard deviation, 60.5 ± 13.5 years) with glioblastoma who underwent preoperative MRI were enrolled in the study. Six hundred and forty-two radiomic features were extracted from volume transfer constant (K<sup>trans</sup>), fractional volume of vascular plasma space (V<sub>p</sub>), and fractional volume of extravascular extracellular space (V<sub>e</sub>) maps of DCE MRI, wherein the regions of interest were based on both T1-weighted contrast-enhancing areas and non-enhancing T2 hyperintense areas. Using feature selection algorithms, salient radiomic features were selected from the 642 features. Next, a radiomics risk score was developed using a weighted combination of the selected features in the discovery set (n = 105); the risk score was validated in the validation set (n = 45) by investigating the difference in prognosis between the "radiomics risk score" groups. Finally, multivariable Cox regression analysis for progression-free survival was performed using the radiomics risk score and clinical variables as covariates.RESULTS: 16 radiomic features obtained from non-enhancing T2 hyperintense areas were selected among the 642 features identified. The radiomics risk score was used to stratify high- and low-risk groups in both the discovery and validation sets (both <i>p</i> &lt; 0.001 by the log-rank test). The radiomics risk score and presence of isocitrate dehydrogenase (IDH) mutation showed independent associations with progression-free survival in opposite directions (hazard ratio, 3.56; <i>p</i> = 0.004 and hazard ratio, 0.34; <i>p</i> = 0.022, respectively).CONCLUSION: We developed and validated the "radiomics risk score" from the features of DCE MRI based on non-enhancing T2 hyperintense areas for risk stratification of patients with glioblastoma. It was associated with progression-free survival independently of IDH mutation status.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?